» Articles » PMID: 19783433

Analogs of a 4-aminothieno[2,3-d]pyrimidine Lead (QB13) As Modulators of P-glycoprotein Substrate Specificity

Overview
Specialty Biochemistry
Date 2009 Sep 29
PMID 19783433
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

P-glycoprotein (P-gp) is an important factor in the development of multidrug resistance (MDR) in cancer cells. In literature reports, a thieno[2,3-d]pyrimidine (QB13) was described as P-gp modulator and opposed effects on the cell accumulation of distinct P-gp substrates were postulated. On the basis of this lead structure, a series of 2-alkylthio-4-aminothieno[2,3-d]pyrimidines was prepared and tested in a daunorubicin accumulation assay. Modulation of substrate specificity was shown for selected compounds in cytotoxicity (MTT) assays.

Citing Articles

Design, Cytotoxicity and Antiproliferative Activity of 4-Amino-5-methyl-thieno[2,3-d]pyrimidine-6-carboxylates against MFC-7 and MDA-MB-231 Breast Cancer Cell Lines.

Mavrova A, Dimov S, Sulikovska I, Yancheva D, Iliev I, Tsoneva I Molecules. 2022; 27(10).

PMID: 35630793 PMC: 9148072. DOI: 10.3390/molecules27103314.


Phosphatase CDC25B Inhibitors Produced by Basic Alumina-Supported One-Pot Gram-Scale Synthesis of Fluorinated 2-Alkylthio-4-aminoquinazolines Using Microwave Irradiation.

Liu J, Wang Y, Zhang J, Yang J, Mou H, Lin J ACS Omega. 2018; 3(4):4534-4544.

PMID: 30221227 PMC: 6130795. DOI: 10.1021/acsomega.8b00640.


Substrate-specific effects of pirinixic acid derivatives on ABCB1-mediated drug transport.

Michaelis M, Rothweiler F, Wurglics M, Aniceto N, Dittrich M, Zettl H Oncotarget. 2016; 7(10):11664-76.

PMID: 26887049 PMC: 4905501. DOI: 10.18632/oncotarget.7345.


Evolution of a thienopyrimidine antitubercular relying on medicinal chemistry and metabolomics insights.

Li S, Vilcheze C, Chakraborty S, Wang X, Kim H, Anisetti M Tetrahedron Lett. 2015; 56(23):3246-3250.

PMID: 26257441 PMC: 4527344. DOI: 10.1016/j.tetlet.2015.02.129.


Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status.

Michaelis M, Rothweiler F, Loschmann N, Sharifi M, Ghafourian T, Cinatl Jr J Oncotarget. 2015; 6(19):17605-20.

PMID: 25749379 PMC: 4627332. DOI: 10.18632/oncotarget.2889.